Efficacy and Safety of STW 5-II for Functional Dyspepsia Treatment: A Patient Data-Based Meta-Analysis
Digestion · 2024
DOI: 10.1159/000535672 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Digestion, 2024. Verfasst von Viola Andresen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medizinicum, Hamburg, Germany. Hauptthemen laut MEDLINE: Dyspepsia, Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Functional dyspepsia (FD) is a chronic relapsing gastroduodenal disorder with limited treatment options. Herbal products, like the six-herb combination STW 5-II, can target multiple FD gastrointestinal symptoms. In this meta-analysis, we evaluated the efficacy and safety of STW 5-II for overall FD, and key symptoms, based on Rome IV criteria.
Methods
We systematically screened the literature for randomized controlled clinical studies testing STW 5-II in FD. Meta-analysis was performed using data from individual patients with at least one key FD symptom (fullness, early satiety, or epigastric pain) of at least moderate severity at baseline. ANCOVA-based meta-analyses were performed on improvements in the total symptom sum score, and single symptoms, after 4 and 8 weeks. Safety data were analyzed by calculating odds ratios for all adverse events.
Results
Four randomized controlled trials, including 613 patients, were identified, and two were eligible for efficacy analysis. STW 5-II significantly improved the FD symptom sum score (mean difference of 1.74 after 4 weeks and 2.07 after 8 weeks) and key FD symptoms of fullness (0.28 and 0.29), early satiety (0.25 and 0.26), and epigastric/upper abdominal pain (0.26 and 0.3). Treatment-related or severe adverse events did not differ between STW 5-II and placebo.
Conclusion
The results support that STW 5-II significantly improves FD symptoms after 4 and 8 weeks of treatment with no difference in relation to safety signals compared to placebo. Thus, STW 5-II can be considered an effective and safe treatment option for FD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medizinicum, Hamburg, Germany.
- Department of Gastroenterology and Hepatology, Princess Alexandra Hospital, Woolloongabba, Brisbane, Queensland, Australia.
- Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
- Digestive Health and Phytomedicine, Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany.
- M.A.R.C.O. GmbH and Co. KG, Institute for Clinical Research and Statistics, Düsseldorf, Germany.
Zitieren
APA
Andresen, V., Shah, A., Fink, C., Rabini, S., Wargenau, M., & Holtmann, G. (2024). Efficacy and Safety of STW 5-II for Functional Dyspepsia Treatment: A Patient Data-Based Meta-Analysis. Digestion. https://doi.org/10.1159/000535672
Vancouver
Andresen V, Shah A, Fink C, Rabini S, Wargenau M, Holtmann G. Efficacy and Safety of STW 5-II for Functional Dyspepsia Treatment: A Patient Data-Based Meta-Analysis. Digestion. 2024. doi:10.1159/000535672
BibTeX
@article{Andresen2024,
author = {Andresen, Viola and Shah, Ayesha and Fink, Careen and Rabini, Sabine and Wargenau, Manfred and Holtmann, Gerald},
title = {Efficacy and Safety of STW 5-II for Functional Dyspepsia Treatment: A Patient Data-Based Meta-Analysis},
journal = {Digestion},
year = {2024},
doi = {10.1159/000535672}
}
EUVIMED